{"id":965990,"date":"2026-05-21T10:38:25","date_gmt":"2026-05-21T14:38:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/"},"modified":"2026-05-21T10:38:25","modified_gmt":"2026-05-21T14:38:25","slug":"when-blood-compatibility-becomes-a-pregnancy-risk","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/","title":{"rendered":"When Blood Compatibility Becomes a Pregnancy Risk"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\">SAN DIEGO<\/span>, <span class=\"legendSpanClass\">May 21, 2026<\/span> \/PRNewswire\/ &#8212; QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 58 of its <i>Science Bytes<\/i> podcast, focusing on hemolytic disease of the fetus and newborn (HDFN) \u2013 a serious but often underrecognized condition driven by maternal alloimmunization.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2984815\/Bethany_Weathersby_Founder_of_the_Allo_Hope_Foundation.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2984815\/Bethany_Weathersby_Founder_of_the_Allo_Hope_Foundation.jpg\" title=\"Bethany Weathersby, Founder of the Allo Hope Foundation\" alt=\"Bethany Weathersby, Founder of the Allo Hope Foundation\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Hosted by Michelle Mullens, Global Product Manager of Portfolio Solutions for Transfusion Medicine at QuidelOrtho, the episode features Bethany Weathersby, Founder and Executive Director of the Allo Hope Foundation. Together, they explore how red blood cell antibodies can impact pregnancy, why awareness and care gaps persist, and how timely diagnostics and coordinated care can dramatically improve outcomes for mothers and babies.<\/p>\n<p>\n        <b>Key Insights:<\/b>\n      <\/p>\n<ul type=\"square\">\n<li>What is HDFN: How maternal alloimmunization leads to red blood cell antibody formation and fetal risk<\/li>\n<li>The impact of awareness gaps: Many patients and providers are unfamiliar with alloantibodies, leading to delayed understanding and care<\/li>\n<li>Why lab testing matters: Antibody screening and titers directly guide pregnancy management and risk assessment<\/li>\n<li>Inconsistencies in care: Outcomes can vary widely depending on provider knowledge, timing of testing and access to specialized care<\/li>\n<li>The patient perspective: Connecting diagnostic workflows to real-world outcomes highlights opportunities to improve care<\/li>\n<\/ul>\n<p>HDFN occurs when a pregnant individual develops antibodies against fetal red blood cell antigens, leading to fetal anemia and other serious complications. While advances in screening and treatment have improved outcomes, the episode highlights ongoing inconsistencies in awareness, access to expertise and clinical management \u2013 even in well-resourced healthcare settings.<\/p>\n<p>Through a powerful combination of clinical insight and lived experience, the conversation highlights the critical role of laboratory testing as the foundation of prenatal care decisions and the importance of acting quickly on results to prevent severe outcomes.<\/p>\n<p>Listen to the latest episode of the <i>QuidelOrtho Science Bytes<\/i> podcast on major streaming platforms or at: <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4693739-1&amp;h=3467222719&amp;u=https%3A%2F%2Fwww.quidelortho.com%2Fglobal%2Fen%2Fresources%2Fpodcasts%2Fquidelortho-science-bytes&amp;a=https%3A%2F%2Fwww.quidelortho.com%2Fglobal%2Fen%2Fresources%2Fpodcasts%2Fquidelortho-science-bytes\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.quidelortho.com\/global\/en\/resources\/podcasts\/quidelortho-science-bytes<\/a>.<\/p>\n<p>\n        <b>About QuidelOrtho Corporation<br \/><\/b>With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes \u2013 from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.<\/p>\n<p>\n        <b>About the Allo Hope Foundation<\/b><br \/>\n        <br \/>The\u00a0Allo\u00a0Hope Foundation (AHF) serves families and clinicians globally navigating red cell alloimmunization and hemolytic disease of the fetus and newborn (HDFN). Led by patients with\u00a0expertise\u00a0in education, research, and clinical practice\u00a0under the oversight of a Medical Advisory Board and Patient Advisory Board, AHF believes\u00a0survival from HDFN should be an expectation and global reality. AHF manages daily patient counsel for thousands of\u00a0families,\u00a0facilitates\u00a0specialty referrals, conducts and\u00a0publishes\u00a0disease research and clinical practice guidelines, and raises global awareness through\u00a0provider education and public health initiatives.\u00a0<\/p>\n<p>Source: QuidelOrtho Corporation<\/p>\n<p>\n        <b>Investor Contact:\u00a0<br \/><\/b>Juliet Cunningham<br \/>Vice President, Investor Relations<br \/><a href=\"mailto:IR@QuidelOrtho.com\" target=\"_blank\" rel=\"nofollow\">IR@QuidelOrtho.com<\/a><\/p>\n<p>\n        <b>Media Contact:\u00a0<br \/><\/b>Stephanie Kleewein<br \/>Senior Corporate Communication and PR Manager<br \/><a href=\"mailto:Media@QuidelOrtho.com\" target=\"_blank\" rel=\"nofollow\">Media@QuidelOrtho.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2984816\/QuidelOrtho_Science_Bytes.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2984816\/QuidelOrtho_Science_Bytes.jpg\" title=\"QuidelOrtho Science Bytes, Episode # 58 - HDFN\" alt=\"QuidelOrtho Science Bytes, Episode # 58 - HDFN\" \/><br \/>\n          <\/a>\n        <\/p>\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2838981\/QuidelOrtho_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2838981\/QuidelOrtho_Logo.jpg\" title=\"QuidelOrtho Corporation (PRNewsfoto\/QuidelOrtho Corporation)\" alt=\"QuidelOrtho Corporation (PRNewsfoto\/QuidelOrtho Corporation)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA64863&amp;sd=2026-05-21\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/when-blood-compatibility-becomes-a-pregnancy-risk-302778272.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/when-blood-compatibility-becomes-a-pregnancy-risk-302778272.html<\/a><\/p>\n<p>SOURCE QuidelOrtho Corporation<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA64863&amp;Transmission_Id=202605210918PR_NEWS_USPR_____LA64863&amp;DateId=20260521\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO, May 21, 2026 \/PRNewswire\/ &#8212; QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic disease of the fetus and newborn (HDFN) \u2013 a serious but often underrecognized condition driven by maternal alloimmunization. Hosted by Michelle Mullens, Global Product Manager of Portfolio Solutions for Transfusion Medicine at QuidelOrtho, the episode features Bethany Weathersby, Founder and Executive Director of the Allo Hope Foundation. Together, they explore how red blood cell antibodies can impact pregnancy, why awareness and care gaps persist, and how timely diagnostics and coordinated care can dramatically improve outcomes for mothers and babies. Key Insights: What is HDFN: How maternal alloimmunization leads &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;When Blood Compatibility Becomes a Pregnancy Risk&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-965990","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>When Blood Compatibility Becomes a Pregnancy Risk - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"When Blood Compatibility Becomes a Pregnancy Risk - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, May 21, 2026 \/PRNewswire\/ &#8212; QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic disease of the fetus and newborn (HDFN) \u2013 a serious but often underrecognized condition driven by maternal alloimmunization. Hosted by Michelle Mullens, Global Product Manager of Portfolio Solutions for Transfusion Medicine at QuidelOrtho, the episode features Bethany Weathersby, Founder and Executive Director of the Allo Hope Foundation. Together, they explore how red blood cell antibodies can impact pregnancy, why awareness and care gaps persist, and how timely diagnostics and coordinated care can dramatically improve outcomes for mothers and babies. Key Insights: What is HDFN: How maternal alloimmunization leads &hellip; Continue reading &quot;When Blood Compatibility Becomes a Pregnancy Risk&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-21T14:38:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2984815\/Bethany_Weathersby_Founder_of_the_Allo_Hope_Foundation.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-blood-compatibility-becomes-a-pregnancy-risk\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-blood-compatibility-becomes-a-pregnancy-risk\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"When Blood Compatibility Becomes a Pregnancy Risk\",\"datePublished\":\"2026-05-21T14:38:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-blood-compatibility-becomes-a-pregnancy-risk\\\/\"},\"wordCount\":525,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-blood-compatibility-becomes-a-pregnancy-risk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2984815\\\/Bethany_Weathersby_Founder_of_the_Allo_Hope_Foundation.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-blood-compatibility-becomes-a-pregnancy-risk\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-blood-compatibility-becomes-a-pregnancy-risk\\\/\",\"name\":\"When Blood Compatibility Becomes a Pregnancy Risk - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-blood-compatibility-becomes-a-pregnancy-risk\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-blood-compatibility-becomes-a-pregnancy-risk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2984815\\\/Bethany_Weathersby_Founder_of_the_Allo_Hope_Foundation.jpg\",\"datePublished\":\"2026-05-21T14:38:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-blood-compatibility-becomes-a-pregnancy-risk\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-blood-compatibility-becomes-a-pregnancy-risk\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-blood-compatibility-becomes-a-pregnancy-risk\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2984815\\\/Bethany_Weathersby_Founder_of_the_Allo_Hope_Foundation.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2984815\\\/Bethany_Weathersby_Founder_of_the_Allo_Hope_Foundation.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-blood-compatibility-becomes-a-pregnancy-risk\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"When Blood Compatibility Becomes a Pregnancy Risk\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"When Blood Compatibility Becomes a Pregnancy Risk - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/","og_locale":"en_US","og_type":"article","og_title":"When Blood Compatibility Becomes a Pregnancy Risk - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, May 21, 2026 \/PRNewswire\/ &#8212; QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic disease of the fetus and newborn (HDFN) \u2013 a serious but often underrecognized condition driven by maternal alloimmunization. Hosted by Michelle Mullens, Global Product Manager of Portfolio Solutions for Transfusion Medicine at QuidelOrtho, the episode features Bethany Weathersby, Founder and Executive Director of the Allo Hope Foundation. Together, they explore how red blood cell antibodies can impact pregnancy, why awareness and care gaps persist, and how timely diagnostics and coordinated care can dramatically improve outcomes for mothers and babies. Key Insights: What is HDFN: How maternal alloimmunization leads &hellip; Continue reading \"When Blood Compatibility Becomes a Pregnancy Risk\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-21T14:38:25+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2984815\/Bethany_Weathersby_Founder_of_the_Allo_Hope_Foundation.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"When Blood Compatibility Becomes a Pregnancy Risk","datePublished":"2026-05-21T14:38:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/"},"wordCount":525,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2984815\/Bethany_Weathersby_Founder_of_the_Allo_Hope_Foundation.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/","name":"When Blood Compatibility Becomes a Pregnancy Risk - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2984815\/Bethany_Weathersby_Founder_of_the_Allo_Hope_Foundation.jpg","datePublished":"2026-05-21T14:38:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2984815\/Bethany_Weathersby_Founder_of_the_Allo_Hope_Foundation.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2984815\/Bethany_Weathersby_Founder_of_the_Allo_Hope_Foundation.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-blood-compatibility-becomes-a-pregnancy-risk\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"When Blood Compatibility Becomes a Pregnancy Risk"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=965990"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965990\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=965990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=965990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=965990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}